Moderna Inc’s coronavirus vaccine is effective against the California variant, and its protection lasts for six months, two new studies find.
In a study, researchers from Duke University found that the antibodies generated by Moderna’s jab had approx. twice less neutralizing force against the tribe first discovered in Golden State.
While it is a decline, the team says the results show the vaccine is still highly effective.
It follows other research that has found that the Moderna vaccine is weakened against the British variant, now the dominant strain in the US, but still very protective.
In another study, researchers from the National Institute of Allergy and Infectious Diseases and Emory University found that neutralizing antibodies remained at high levels for at least six months.
However, the Centers for Disease Control and Prevention (CDC) reports that although Moderna̵
In one study, researchers at Duke University exposed blood samples from humans who had received both doses of the Moderna coronavirus vaccine for the California variant. The picture: A vial of Modernas COVID-19 vaccine, 7 April
The protective ability has only slightly decreased with antibodies that have twice the neutralizing effect (center), enough to still be very effective in preventing infection
For the first study, published in The New England Journal of Medicine, the Duke team looked at blood samples from 26 people who had received both doses of the Moderna vaccine.
The serum was then subjected to the Californian variant known as B.1.427 / B.1.429.
The variant was first identified in May 2020 and was almost non-existent until October.
In a recent study, the University of California, San Francisco, examined 2,172 samples of the virus collected between September 2020 and January 2021 across California.
In January, the new variant accounted for more than 50 percent of all genetically analyzed coronavirus samples.
In short, it had become the most common strain in California and can account for up to 90 percent of state infections.
The team says this is good news because it shows that the Moderna vaccine is protective against the most widespread variant in California
Laboratory studies performed by the USCF showed that B.1.427 / B.1.429 produced a viral load twice as high as that triggered by other variants.
This suggests that the homemade variant is better at copying faster when it enters the human body and hijacks its machines.
The new study showed that the protective ability of the Moderna vaccine against the California vaccine only decreased slightly, by approx. twice less neutralizing power.
However, antibodies generated by the vaccine had 6.7 to 9.7 times less neutralizing effect against the South African variant.
The team says this is good news, because while the California variety is widespread in the most populous U.S. state, the South African varieties are not very widespread.
‘The good news is that the California variant does not appear to be a problem for our current vaccines,’ said study author Dr.
‘It is important to know because this variant is now as prevalent in the United States as the British variant, both of which appear to be more contagious.’
In another study, the researchers found that antibody levels remained high in all age groups six months after receiving the first dose.
A new CDC report found that Moderna recipients were more likely to report reactions after receiving a dose compared to the Pfizer-BioNTech vaccine. The picture: A healthcare worker receives the Moderna Inc Covid-19 vaccine in Tucson, Arizona, January 2021
For the second study, which was also published in the New England Journal of Medicine, the team looked at blood samples from 33 healthy participants.
All had been dosed in the Phase I trial, and researchers looked at levels of binding and neutralizing antibodies more than 200 days after the first dose.
Among all age groups, antibody activity levels remained high after six months.
”[A]antibodies induced by [the vaccine] continued for six months after the second dose, ‘the authors wrote.
Ongoing studies monitor the immune response beyond six months and determine the effect of a booster dose to prolong the duration and breadth of activity against new viral variants.
The report repeats what Pfizer-BioNTech reported last week about their coronavirus vaccine, which works in the same way as Moderna’s jab.
However, despite reports of Moderna’s protective capability, recipients report more side effects than those who received the Pfizer-BioNTech shot.
In a new study published in JAMA, CDC researchers look at reports collected through V-SAFE, which use text messaging and web surveys so that immunization recipients can write down if they experience side effects.
After the first dose, subjects receiving Moderna inoculation were more likely to report adverse reactions.
For example, 73.9 percent of Moderna recipients reported an injection site reaction, such as pain or redness, compared with 65.4 percent of people receiving Pfizer.
In addition, 51.7 percent of those who received Moderna reported reactions such as headaches, fever, or chills compared to 48 percent of Pfizer recipients.
The difference between the two vaccines increased after the second dose.
A total of 81.9 percent of Moderna recipients reported an injection site reaction, and 74.8 percent reported other adverse reactions.
In comparison, 68.6 percent of those who received Pfizer jab reported injection reactions, and 64.2 had other symptoms.
It is unclear why more people getting the Moderna shot report side effects.
The National Institutes of Health is now launching a study looking at why some people have suffered allergic reactions from the Pfizer and Moderna vaccines.